Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
62
resultados
Última actualización
31/08/2025 [06:45:00]
Resumen de: WO2025178607A1
A method and apparatus for labeling a tissue section is provided. In certain aspects, the methods comprise labeling a tissue sample via a plurality of immunohistochemistry (IHC) assays for detection of markers for characterization of a non-Hodgkin's lymphoma. The disclosed IHC assays employ chromogen-based detection methods for improved sample efficiency and visualization of biomarkers. Further disclosed is an apparatus for carrying out the disclosed methods.
Resumen de: WO2025176039A1
Provided are use of an IL-1α inhibitor in preparing a medicament for treating leukemia therapy-induced cardiac injury and use of an IL1R1 antagonist in preparing a medicament for treating leukemia therapy-induced cardiac injury. The present disclosure can effectively reduce cardiovascular complications and the occurrence of long-term cardiovascular adverse events in the period of leukemia treatments, thereby helping alleviate the cardiac metabolic dysfunction and cardiac dysfunction after treatment.
Resumen de: US2025268844A1
The invention discloses novel 5-substituted 4-hydroxy-cyclopent-2-en-1-one derivatives as active compounds in pharmaceutical compositions for the treatment of cancer. The invention confers cytotoxic effects of the said compounds on ovarian, colorectal, cervical, hepatocellular, lung, bladder and breast carcinomas, melanoma, lymphoma, leukemia and myeloma malignant cells, for the inhibition of cell cycle progression at the G2/M phase, for reducing the expression of DNA replication licensing factors and for having general cancer treatment effects. It further discloses the use of the said compositions for the treatment of platinum-resistant tumors. Another aspect of the invention is the synergetic effects of these compounds with existing cancer treatment medicaments as the proteasomal inhibitors. Finally, the synthetic methods of the active compounds of the said com-positions are disclosed.
Resumen de: US2025269048A1
The present invention relates bispecific antibodies and antigen binding fragments thereof for binding to CD33 and CD7 for use in treating CD33+ CD7+ hematological malignancies, and in particular Acute Myeloid Leukaemia (AML). In particular, the present invention relates to a bispecific antibody or antigen binding fragments thereof binding to CD33 and CD7, wherein the bispecific antibody or antigen binding fragments comprises a first binding region binding to human CD33 which comprises the sequences having at least 95% sequence identity to sequences: VH SEQ ID No. 81; and VL SEQ ID No. 85, and a second binding region binding to human CD7 which comprises the a VH sequence and a VL sequence having at least 95% sequence identity to the following sequences: VH SEQ ID No. 11; VH SEQ ID No. 21; VH SEQ ID No. 31; VH SEQ ID No. 51; VH SEQ ID No. 71; VL SEQ ID No. 15; VL SEQ ID No. 25; VL SEQ ID No. 35; VL SEQ ID No. 55; and VL SEQ ID No. 75 or wherein the bispecific antibody or antigen binding fragments comprises a first binding region binding to human CD33 which comprises the sequences having at least 95% sequence identity to sequences: VH SEQ ID No. 97; and VL SEQ ID No. 101, and a second binding region binding to human CD7 which comprises the a VH sequence and a VL sequence having at least 95% sequence identity to the following sequences: VH SEQ ID No. 1; VH SEQ ID No. 51; VH SEQ ID No. 71; VL SEQ ID No. 5; VL SEQ ID No. 55; and VL SEQ ID No. 75.
Resumen de: US2025269024A1
Provided herein are methods of treating a subject who has multiple myeloma and has received an initial therapy, including a stem cell transplantation. Infusions of chimeric antigen receptor (CAR)-T cells comprising a BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×105 to 5.0×106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
Resumen de: US2025269012A1
An oncolytic group B adenovirus suitable for treating a solid tumor (for example sarcoma, carcinoma and/or lymphoma) comprising a sequence of formula (I): 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR (I) wherein: a first transgene encodes a polypeptide comprising a target-sequence specific for a binding domain on the cells of a cell-based immunotherapy, for example bearing a (exogenous) recombinant surface expressed protein, such as a chimeric antigen receptor or an NKG2D receptor, in particular wherein the target-sequence specifically binds to said surface expressed protein (more especially the chimeric antigen receptor) on the immunotherapy cell; and a second transgene encodes a polypeptide comprising a molecule that promotes trafficking of the cell-based immunotherapy into and within the tumor.
Resumen de: US2025268941A1
The present disclosure relates to BCMA/CD19 CAR T-cell products and methods for treating relapsed or refractory BCMA+ or CD19+ malignancies.
Resumen de: US2025270254A1
The present disclosure provides a probe specifically binding to CD138, a kit and a microfluidic chip comprising the probe, and a method of diagnosing diffuse large B-cell lymphoma in a subject using the probe, the kit, or the microfluidic chip. The present disclosure also provides a method of screening the probe for diagnosing diffuse large B-cell lymphoma.
Resumen de: US2025269065A1
Provided herein is a gene therapy for BAG3 (B-cell Lymphoma 2-Associated Anthanogene 3), e.g., using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter, a cardiac troponin T (hTNNT2) promoter, a heat shock protein 70 (HSP70) promoter, or a ubiquitin C (UBC) promoter. The capsid may be an AAVrh.74 or AAV9 capsid or a functional variant thereof. In certain embodiments, the capsid is an AAVrh.74 capsid or functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the AAV vector, and other compositions and methods.
Resumen de: US2025268920A1
Provided is a method for treating a blood cancer in an individual in need thereof by administrating to the individual an agent that inhibits activity or expression of one or more enzymes that participate in synthesis of either or both dihydrotestosterone (DHT) or androgen receptor (AR), or an antagonist AR, or a combination of an agent and the antagonist. The methods are shown in connection with acute myeloid leukemia (AML).
Resumen de: US2025268878A1
The invention relates to the use of ferroportin inhibitor compounds of the general formula (I)for treating myelodysplastic syndromes (MDS).
Resumen de: AU2025213596A1
Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid 5 residue positions 33 to 109 of human integrin β7. Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid 5 residue positions 33 to 109 of human integrin ß7. ug r o v i d e d i s a n a c t i v e i n g r e d i e n t o f a p h a r m a c e u t i c a l u g c o m p o s i t i o n f o r t r e a t i n g m y e l o m a p e c i f i c a l l y , p r o v i d e d i s a n a n t i b o d y w h o s e e p i t o p e i s p r e s e n t i n t h e r e g i o n o f t h e a m i n o a c i d r e s i d u e p o s i t i o n s t o o f h u m a n i n t e g r i n ß
Resumen de: AU2025217281A1
Provided herein, in some embodiments, are methods for reducing the risk of developing progressive multifocal leukemia in patients undergoing natalizumab therapy by switching to an extended interval dosing (EID) schedule. Provided herein, in some embodiments, are methods for reducing the risk of developing progressive multifocal leukemia in patients undergoing natalizumab therapy by switching to an extended interval dosing (EID) schedule. ug r o v i d e d h e r e i n , i n s o m e e m b o d i m e n t s , a r e m e t h o d s f o r r e d u c i n g t h e r i s k o f d e v e l o p i n g p r o g r e s s i v e m u l t i f o c a l l e u k e m i a i n p a t i e n t s u n d e r g o i n g n a t a l i z u m a b t h e r a p y b y u g s w i t c h i n g t o a n e x t e n d e d i n t e r v a l d o s i n g ( ) s c h e d u l e
Resumen de: US2025270193A1
The present disclosure provides compounds which are useful in the treatment of oncological disorders, more particularly arylimidamides useful in the treatment of leukemias. Exemplary compounds include an azole moiety connected to a phenoxy or pyridyloxy moiety via an alkylene chain, the phenoxy or pyridyloxy moiety attached to a benzimidamide or pyridylimidamide function.
Resumen de: WO2025174079A1
The present invention relates to a composition comprising an anti-CD20 antibody and a PIKfyve inhibitor for preventing or treating CD20 positive cancer such as B cell lymphoma. The present invention can maximize the anticancer effect of an anti-CD20 antibody, specifically, obinutuzumab, by co-administering an anti-CD20 antibody and a PIKfyve inhibitor, which is a negative regulator of a tumor cell killing mechanism thereof. In addition, by using PIKfyve as a screening target, the present invention can rapidly identify, with high reliability, combination therapy candidate agents that can synergistically enhance the direct cell death (DCD), lysosomal membrane permeabilization (LMP), and subsequent cancer cell-killing activity of anti-CD20 antibodies.
Resumen de: US2025263740A1
An object of the present invention is to provide a novel non-replicating bovine leukemia virus (BLV) and a producing cell thereof. According to the present invention, there is provided a bovine leukemia virus (BLV) in which at least a part of the function of a pol gene is deficient. Also, according to the present invention, there is provided a non-replicating BLV-producing cell comprising a gene of a BLV in which at least a part of the function of a pol gene is deficient. The present invention is advantageous in that it can provide a BLV vaccine which is highly immunogenic, and is highly safe without replicating in an infected subject.
Resumen de: US2025262299A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies and lenalidomide.
Resumen de: US2025263412A1
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a heteroaryl substituted oxadiazole structure which function as non-hydroxamate histone deacetylase 6 (HDAC6) inhibitors, and their use as therapeutics for the treatment of metabolic disorders (e.g., obesity, Diabetes), neurological disorders (e.g., Alzheimer's disease, Parkinson disease, Huntington disease), cancer (e.g., multiple myeloma, biliary tract cancer, non-small cell lung cancer, chronic lymphocytic leukemia) and other conditions related to HDAC6 activity (e.g., Rett syndrome (RTT), inherited retinal disorders (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT)).
Resumen de: WO2025174664A1
Minor histocompatibility antigens (mHAgs) associated with graft versus leukemia (GvL) clinical outcomes identified by single nucleotide polymorphisms (SNPS) and uses thereof are described.
Resumen de: US2025263440A1
A peptide, compound, or conjugate that can bind CD38. The CD38-binding peptide, compound, or conjugate has a sequence selected from the group consisting of SEQ ID NOs. 1-34. The CD38-binding peptides, compounds, or conjugates are useful for treating CD38-associated conditions, disorders, or diseases, such as cancer, leukemia, or myelomas.
Resumen de: WO2024077376A1
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of myelodysplastic syndrome (MDS) or leukemia such as AML is also described.
Resumen de: WO2025170888A1
Provided herein are combination therapies for treating blood cancer, in particular, acute myeloid leukemia, by concurrently targeting AXL and PD-1.
Resumen de: WO2025169136A1
The present disclosure provides, among other things, a method for treating cancer by administering two or more doses of cord blood derived natural killer cells expressing CD19 targeted chimeric antigen receptor to a subject in need thereof. The present disclosure provides a dosing regimen, for example, 800 million CD19 CAR NK cells administered in three doses for treating a cancer, for example, relapsed or refractory large B cell lymphoma.
Resumen de: WO2025168847A1
The present disclosure relates to a combination of a chimeric antigen receptor (CAR) and a modified CD200 receptor (CD200R). More in particular, a combination of a CAR targeting an antigen highly expressed in cancers which also typically express CD200, such as Hodgkin lymphoma, with a modified CD200R has been found useful in the treatment of such cancers. The present disclosure further relates to polynucleic acids, vectors, immune cells, pharmaceutical compositions encoding or comprising said combination, the same for use in the treatment of cancer and methods of preparation of said immune cells.
Nº publicación: WO2025170902A1 14/08/2025
Solicitante:
LEGEND BIOTECH USA INC [US]
JANSSEN BIOTECH INC [US]
LEGEND BIOTECH USA INC,
JANSSEN BIOTECH, INC
Resumen de: WO2025170902A1
Provided herein are methods of treating a subject who has multiple myeloma and has received an initial therapy, including a stem cell transplantation. Infusions of chimeric antigen receptor (CAR)-T cells comprising a BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 x 105 to 5.0 x 106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
BOPI
Sede Electrónica
